NSE: DIVISLAB | BSE: 532488

Expensive Star

Download real time

6012.50 -203.00 (-3.27%)

New 52W High in past week

980.2K NSE+BSE Volume

NSE 25 Apr, 2025 3:31 PM (IST)

159,613

Market Cap

Market Runner Up

0.7

Beta 1Year

Very Low volatility

Divi's Laboratories Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for DIVISLAB, BSE:532488 Divi's Laboratories Ltd.

Divi's Laboratories Ltd.

04 Aug 2024

6012.50

-3.27%

Generic business disappoints; valuations a tad pricey

Sell: Divi's Laboratories Ltd.

Recommendation Target

ICICI Securities Limited

Divi’s Laboratories’ (Divi’s) Q1FY25 result was sub-par. Revenue traction was driven by custom synthesis (CS) (up ~46% YoY), while generics grew 1.5% YoY due to double-digit price erosion in key products like Naproxen, Gabapentin and Dexamethasone.

Number of FII/FPI investors increased from 826 to 922 in Mar 2025 qtr.

Divi's Laboratories Ltd.

29 May 2024

6012.50

-3.27%

Divis Lab

Results Update: Divi's Laboratories Ltd.

SMC online

Divi's Laboratories .. has an average target of 5832.12 from 9 brokers.

Divi's Laboratories Ltd.

28 May 2024

6012.50

-3.27%

Ramp up in custom synthesis and new generic APIs to drive margins

Hold: Divi's Laboratories Ltd.

Target

KRChoksey

The likely beginning of supply of newly going off patent product’s APIs, ramp up in contrast media and Sartan products’ generic APIs as well as in the ongoing custom synthesis projects will fuel improved margins over short – long term.
The new supply agreement with an MNC client and peptide ingredients opportunity present ample scope for valuation multiple expansion in the medium term.

Divi's Laboratories Ltd. is trading above all available SMAs

Divi's Laboratories Ltd.

27 May 2024, 12:00AM

6012.50

-3.27%

Divi's Laboratories

Hold: Divi's Laboratories Ltd.

Recommendation Target

ICICI Direct

Divi's Laboratories Ltd. is trading above all available SMAs

Divi's Laboratories Ltd.

25 May 2024

6012.50

-3.27%

Divi's Labs (SELL): Strong quarter; rich valuations

Sell: Divi's Laboratories Ltd.

BOB Capital Markets Ltd.

DIVI delivered a strong quarter with all round beat. EBITDA/PAT beat Bloomberg consensus estimate by 20% each

Divi's Laboratories Ltd. is trading above all available SMAs

Divi's Laboratories Ltd.

03 Apr 2024

6012.50

-3.27%

Value play among API exports players

Accumulate: Divi's Laboratories Ltd.

KRChoksey

We believe Divi’s Labs Ltd. (DIVISLAB) has strong growth engines ahead to augment its growth and profitability over FY23-FY26E. During FY22-FY24E, it has been validating existing generic contrast media APIs and Sartan products with new set of potential customers as well as novel MRI API with innovator pharma company.

Divi's Laboratories Ltd. is trading above all available SMAs

Divi's Laboratories Ltd.

15 Feb 2024

6012.50

-3.27%

Result update - Divis Lab

Results Update: Divi's Laboratories Ltd.

SMC online

Divi's Laboratories .. has an average target of 5832.12 from 9 brokers.

Divi's Laboratories Ltd.

12 Feb 2024

6012.50

-3.27%

First Light | LIC, Alkem Labs, Monthly Chartbook, Power Grid Corp, Tata Consumer Products, Divi's Labs, Torrent Power, Escorts, The Ramco Cements, Metals & Mining

Sell: Divi's Laboratories Ltd.

BOB Capital Markets Ltd.

LICI: Solid quarter; valuations overdone cut to HOLD. ALKEM: Good quarter; cut to SELL on stretched valuations. Monthly Chartbook: Fiscal consolidation to hold key. PWGR: In-line quarter, FY25 capex hiked; maintain BUY. TATACONS: Strong run continues. DIVI: Healthy margin recovery, heady valuations. TPW: Dull quarter; high valuations maintain HOLD. ESCORTS: Weakness persists - maintain SELL. TRCL: Tepid quarter, high capex overhang retain SELL. Metals & Mining: Ferrous read-across: Steel recovery in CY24 - ArcelorMittal